Recent Finacing
Recent Raise
SK Biopharmaceuticals develops YKP3089 for refractory epilepsy (late Phase 2) and provides API and intermediate manufacturing in Korean factories, with R&D in Daejeon and clinical in New Jersey.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at SK biopharmaceuticals.
